Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma.

Saved in:
Bibliographic Details
Title: Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma.
Authors: Karapetyan L; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Cillo AR; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Wang S; UPMC Hillman Cancer Center Biostatistics Facility, Pittsburgh, PA, USA., Karunamurthy A; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Massa RC; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, PA, USA., Rohatgi A; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, United States; Alvin J. Siteman Cancer Center, St Louis, MO, USA., Deitrick C; UPMC Hillman Cancer Center Bioinformatics services, Pittsburgh, PA, USA., Najjar YG; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA., Davar D; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA., Luke JJ; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA., Sander C; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Kunning SR; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA., Rose A; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Bradley S; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Rush E; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Joy M; Translational pathology imaging laboratory, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Bao R; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center Bioinformatics services, Pittsburgh, PA, USA., Wang H; UPMC Hillman Cancer Center Biostatistics Facility, Pittsburgh, PA, USA., Vignali DAA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Co-senior authors., Bruno TC; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Co-senior authors., Kirkwood JM; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Co-senior authors.; Lead contact.
Source: MedRxiv : the preprint server for health sciences [medRxiv] 2025 Nov 06. Date of Electronic Publication: 2025 Nov 06.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
DOI:10.1101/2025.11.04.25339499